Skip to content

Study · Non-randomized trial · n = 11 · 2005

19 results

Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.

Jørgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LØ, Hagen C, Ørskov H

The Journal of clinical endocrinology and metabolism26 Jul 2005Cited by 117 (Europe PMC)

PMID16046586 (opens in a new tab)DOI10.1210/jc.2005-0531 (opens in a new tab)PepBankPUB-16046586
Source linkPubMedAsk about this study
Jump to 19 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study19

19 results from studies that gave the peptide. 19 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, total IGF-I fell from 562 +/- 78 off therapy to 376 +/- 51 micrograms per liter during pegvisomant 10 mg/d.

    In plain wordsIn acromegaly patients, pegvisomant 10 mg/d reduced total IGF-I compared with the off-therapy phase.

    Peptide
    Pegvisomant
    Outcome
    DecreaseTotal serum IGF-I at 10 mg/d
    Study

    n = 11

    Comparator
    Off-therapy active phase
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    10 mg/d · 6 weeksAs given in this study (human).

    Measurements

    Total IGF-I
    376 micrograms per liter
    10 mg
    Total IGF-I
    562 micrograms per liter
    active

    Source sentences

    Summary
    Total serum IGF-I levels (micrograms per liter) decreased after pegvisomant, but the lowest levels were obtained with cotreatment [458 +/- 67 (SMS), 562 +/- 78 (active), 376 +/- 51 (10 mg), 269 (15 mg), 195 +/- 24 (combined) (P < 0.0001)].
    2 context sentences
    Summary · context
    Eleven patients with persistent disease despite previous therapy underwent the following fixed treatment algorithm: 1) on SMS therapy, 2) off therapy for 2 months, 3) 6-wk treatment with 10 mg/d pegvisomant, 4) 6-wk treatment with 15 mg/d pegvisomant, and 5) 3-month treatment with 15 mg pegvisomant plus SMS.
    Summary · context
    Blood was sampled in the fasting state and during an oral glucose tolerance test.
  2. 02HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, total IGF-I fell from 562 +/- 78 off therapy to 269 micrograms per liter during pegvisomant 15 mg/d.

    In plain wordsIn acromegaly patients, pegvisomant 15 mg/d reduced total IGF-I compared with the off-therapy phase.

    Peptide
    Pegvisomant
    Outcome
    DecreaseTotal serum IGF-I at 15 mg/d
    Study

    n = 11

    Comparator
    Off-therapy active phase
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    15 mg/d · 6 weeksAs given in this study (human).

    Measurements

    Total IGF-I
    269 micrograms per liter
    15 mg
    Total IGF-I
    562 micrograms per liter
    active

    Source sentences

    Summary
    Total serum IGF-I levels (micrograms per liter) decreased after pegvisomant, but the lowest levels were obtained with cotreatment [458 +/- 67 (SMS), 562 +/- 78 (active), 376 +/- 51 (10 mg), 269 (15 mg), 195 +/- 24 (combined) (P < 0.0001)].
    2 context sentences
    Summary · context
    Eleven patients with persistent disease despite previous therapy underwent the following fixed treatment algorithm: 1) on SMS therapy, 2) off therapy for 2 months, 3) 6-wk treatment with 10 mg/d pegvisomant, 4) 6-wk treatment with 15 mg/d pegvisomant, and 5) 3-month treatment with 15 mg pegvisomant plus SMS.
    Summary · context
    Blood was sampled in the fasting state and during an oral glucose tolerance test.
  3. 03HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, free IGF-I changed in a pattern similar to total IGF-I, which decreased after pegvisomant.

    In plain wordsIn acromegaly patients, free IGF-I changed in a similar pattern to total IGF-I, which fell after pegvisomant.

    Peptide
    Pegvisomant
    Outcome
    DecreaseFree IGF-I
    Study

    n = 11

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Free and bioactive IGF-I changed in a similar pattern.
    3 context sentences
    Summary · context
    Total serum IGF-I levels (micrograms per liter) decreased after pegvisomant, but the lowest levels were obtained with cotreatment [458 +/- 67 (SMS), 562 +/- 78 (active), 376 +/- 51 (10 mg), 269 (15 mg), 195 +/- 24 (combined) (P < 0.0001)].
    Summary · context
    Eleven patients with persistent disease despite previous therapy underwent the following fixed treatment algorithm: 1) on SMS therapy, 2) off therapy for 2 months, 3) 6-wk treatment with 10 mg/d pegvisomant, 4) 6-wk treatment with 15 mg/d pegvisomant, and 5) 3-month treatment with 15 mg pegvisomant plus SMS.
    Summary · context
    Blood was sampled in the fasting state and during an oral glucose tolerance test.
  4. 04HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, bioactive IGF-I changed in a pattern similar to total IGF-I, which decreased after pegvisomant.

    In plain wordsIn acromegaly patients, bioactive IGF-I changed in a similar pattern to total IGF-I, which fell after pegvisomant.

    Peptide
    Pegvisomant
    Outcome
    DecreaseBioactive IGF-I
    Study

    n = 11

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Free and bioactive IGF-I changed in a similar pattern.
    3 context sentences
    Summary · context
    Total serum IGF-I levels (micrograms per liter) decreased after pegvisomant, but the lowest levels were obtained with cotreatment [458 +/- 67 (SMS), 562 +/- 78 (active), 376 +/- 51 (10 mg), 269 (15 mg), 195 +/- 24 (combined) (P < 0.0001)].
    Summary · context
    Eleven patients with persistent disease despite previous therapy underwent the following fixed treatment algorithm: 1) on SMS therapy, 2) off therapy for 2 months, 3) 6-wk treatment with 10 mg/d pegvisomant, 4) 6-wk treatment with 15 mg/d pegvisomant, and 5) 3-month treatment with 15 mg pegvisomant plus SMS.
    Summary · context
    Blood was sampled in the fasting state and during an oral glucose tolerance test.
  5. 05HumanNon-randomized trialPharmacokinetics

    In acromegaly patients, steady-state pegvisomant during 10 mg/d treatment was 2631 +/- 616 micrograms per liter.

    In plain wordsIn acromegaly patients, blood pegvisomant reached 2631 +/- 616 micrograms per liter during 10 mg/d treatment.

    Peptide
    Pegvisomant
    Outcome
    Not applicableSteady-state pegvisomant at 10 mg/d
    Study

    n = 11

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    10 mg/d · 6 weeksAs given in this study (human).

    Measurements

    Steady-state pegvisomant
    2631 micrograms per liter
    10 mg

    Source sentences

    Summary
    Steady-state pegvisomant levels (micrograms per liter) were obtained, but SMS cotreatment increased pegvisomant levels by 20% (P = 0.02) [2631 +/- 616 (10 mg), 6536 +/- 1413 (15 mg), 8030 +/- 1914 (combined)].
    2 context sentences
    Summary · context
    Eleven patients with persistent disease despite previous therapy underwent the following fixed treatment algorithm: 1) on SMS therapy, 2) off therapy for 2 months, 3) 6-wk treatment with 10 mg/d pegvisomant, 4) 6-wk treatment with 15 mg/d pegvisomant, and 5) 3-month treatment with 15 mg pegvisomant plus SMS.
    Summary · context
    Blood was sampled in the fasting state and during an oral glucose tolerance test.
  6. 06HumanNon-randomized trialPharmacokinetics

    In acromegaly patients, steady-state pegvisomant during 15 mg/d treatment was 6536 +/- 1413 micrograms per liter.

    In plain wordsIn acromegaly patients, blood pegvisomant reached 6536 +/- 1413 micrograms per liter during 15 mg/d treatment.

    Peptide
    Pegvisomant
    Outcome
    Not applicableSteady-state pegvisomant at 15 mg/d
    Study

    n = 11

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    15 mg/d · 6 weeksAs given in this study (human).

    Measurements

    Steady-state pegvisomant
    6536 micrograms per liter
    15 mg

    Source sentences

    Summary
    Steady-state pegvisomant levels (micrograms per liter) were obtained, but SMS cotreatment increased pegvisomant levels by 20% (P = 0.02) [2631 +/- 616 (10 mg), 6536 +/- 1413 (15 mg), 8030 +/- 1914 (combined)].
    2 context sentences
    Summary · context
    Eleven patients with persistent disease despite previous therapy underwent the following fixed treatment algorithm: 1) on SMS therapy, 2) off therapy for 2 months, 3) 6-wk treatment with 10 mg/d pegvisomant, 4) 6-wk treatment with 15 mg/d pegvisomant, and 5) 3-month treatment with 15 mg pegvisomant plus SMS.
    Summary · context
    Blood was sampled in the fasting state and during an oral glucose tolerance test.
  7. 07HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, endogenous GH rose from 8.9 +/- 2.9 off therapy to 14.6 +/- 4.9 micrograms per liter during pegvisomant 10 mg/d.

    In plain wordsIn acromegaly patients, pegvisomant 10 mg/d increased natural GH compared with the off-therapy phase.

    Peptide
    Pegvisomant
    Outcome
    IncreaseEndogenous GH at 10 mg/d
    Study

    n = 11

    Comparator
    Off-therapy active phase
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    10 mg/d · 6 weeksAs given in this study (human).

    Measurements

    GH
    14.6 micrograms per liter
    10 mg
    GH
    8.9 micrograms per liter
    active

    Source sentences

    Summary
    Pegvisomant increased endogenous GH levels (micrograms per liter), which was countered by SMS cotreatment [5.1 +/- 1.3 (SMS), 8.9 +/- 2.9 (active), 14.6 +/- 4.9 (10 mg), 19.7 +/- 6.5 (15 mg), 11.8 +/- 2.8 (combined) (P < 0.01)].
    2 context sentences
    Summary · context
    Eleven patients with persistent disease despite previous therapy underwent the following fixed treatment algorithm: 1) on SMS therapy, 2) off therapy for 2 months, 3) 6-wk treatment with 10 mg/d pegvisomant, 4) 6-wk treatment with 15 mg/d pegvisomant, and 5) 3-month treatment with 15 mg pegvisomant plus SMS.
    Summary · context
    Blood was sampled in the fasting state and during an oral glucose tolerance test.
  8. 08HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, endogenous GH rose from 8.9 +/- 2.9 off therapy to 19.7 +/- 6.5 micrograms per liter during pegvisomant 15 mg/d.

    In plain wordsIn acromegaly patients, pegvisomant 15 mg/d increased natural GH compared with the off-therapy phase.

    Peptide
    Pegvisomant
    Outcome
    IncreaseEndogenous GH at 15 mg/d
    Study

    n = 11

    Comparator
    Off-therapy active phase
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    15 mg/d · 6 weeksAs given in this study (human).

    Measurements

    GH
    19.7 micrograms per liter
    15 mg
    GH
    8.9 micrograms per liter
    active

    Source sentences

    Summary
    Pegvisomant increased endogenous GH levels (micrograms per liter), which was countered by SMS cotreatment [5.1 +/- 1.3 (SMS), 8.9 +/- 2.9 (active), 14.6 +/- 4.9 (10 mg), 19.7 +/- 6.5 (15 mg), 11.8 +/- 2.8 (combined) (P < 0.01)].
    2 context sentences
    Summary · context
    Eleven patients with persistent disease despite previous therapy underwent the following fixed treatment algorithm: 1) on SMS therapy, 2) off therapy for 2 months, 3) 6-wk treatment with 10 mg/d pegvisomant, 4) 6-wk treatment with 15 mg/d pegvisomant, and 5) 3-month treatment with 15 mg pegvisomant plus SMS.
    Summary · context
    Blood was sampled in the fasting state and during an oral glucose tolerance test.
  9. 09HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, two-hour OGTT glucose was 7.2 +/- 0.7 during pegvisomant 10 mg/d versus 8.9 +/- 0.7 millimoles per liter off therapy.

    In plain wordsIn acromegaly patients, pegvisomant 10 mg/d produced lower glucose after a glucose test than the off-therapy phase.

    Peptide
    Pegvisomant
    Outcome
    DecreaseTwo-hour OGTT glucose at 10 mg/d versus active phase
    Study

    n = 11

    Comparator
    Off-therapy active phase
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 mg/d · 6 weeksAs given in this study (human).

    Measurements

    Two-hour OGTT glucose
    7.2 millimoles per liter
    10 mg
    Two-hour OGTT glucose
    8.9 millimoles per liter
    active

    Source sentences

    Summary
    Plasma glucose levels (millimoles per liter) were highest during SMS and lowest during pegvisomant 15 mg [2-h oral glucose tolerance test: 10.3 +/- 0.7 (SMS), 8.9 +/- 0.7 (active), 7.2 +/- 0.7 (10 mg), 6.5 +/- 0.5 (15 mg), 8.0 +/- 0.8 (combined) (P = 0.02)].
    2 context sentences
    Summary · context
    Eleven patients with persistent disease despite previous therapy underwent the following fixed treatment algorithm: 1) on SMS therapy, 2) off therapy for 2 months, 3) 6-wk treatment with 10 mg/d pegvisomant, 4) 6-wk treatment with 15 mg/d pegvisomant, and 5) 3-month treatment with 15 mg pegvisomant plus SMS.
    Summary · context
    Blood was sampled in the fasting state and during an oral glucose tolerance test.
  10. 10HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, two-hour OGTT glucose was 6.5 +/- 0.5 during pegvisomant 15 mg/d versus 8.9 +/- 0.7 millimoles per liter off therapy.

    In plain wordsIn acromegaly patients, pegvisomant 15 mg/d produced lower glucose after a glucose test than the off-therapy phase.

    Peptide
    Pegvisomant
    Outcome
    DecreaseTwo-hour OGTT glucose at 15 mg/d versus active phase
    Study

    n = 11

    Comparator
    Off-therapy active phase
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mg/d · 6 weeksAs given in this study (human).

    Measurements

    Two-hour OGTT glucose
    6.5 millimoles per liter
    15 mg
    Two-hour OGTT glucose
    8.9 millimoles per liter
    active

    Source sentences

    Summary
    Plasma glucose levels (millimoles per liter) were highest during SMS and lowest during pegvisomant 15 mg [2-h oral glucose tolerance test: 10.3 +/- 0.7 (SMS), 8.9 +/- 0.7 (active), 7.2 +/- 0.7 (10 mg), 6.5 +/- 0.5 (15 mg), 8.0 +/- 0.8 (combined) (P = 0.02)].
    2 context sentences
    Summary · context
    Eleven patients with persistent disease despite previous therapy underwent the following fixed treatment algorithm: 1) on SMS therapy, 2) off therapy for 2 months, 3) 6-wk treatment with 10 mg/d pegvisomant, 4) 6-wk treatment with 15 mg/d pegvisomant, and 5) 3-month treatment with 15 mg pegvisomant plus SMS.
    Summary · context
    Blood was sampled in the fasting state and during an oral glucose tolerance test.
  11. 11HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, two-hour OGTT glucose was 7.2 +/- 0.7 during pegvisomant 10 mg/d versus 10.3 +/- 0.7 millimoles per liter during SMS.

    In plain wordsIn acromegaly patients, pegvisomant 10 mg/d produced lower glucose after a glucose test than the SMS phase.

    Peptide
    Pegvisomant
    Outcome
    DecreaseTwo-hour OGTT glucose at 10 mg/d versus SMS
    Study

    n = 11

    Comparator
    SMS therapy phase
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 mg/d · 6 weeksAs given in this study (human).

    Measurements

    Two-hour OGTT glucose
    7.2 millimoles per liter
    10 mg
    Two-hour OGTT glucose
    10.3 millimoles per liter
    SMS

    Source sentences

    Summary
    Plasma glucose levels (millimoles per liter) were highest during SMS and lowest during pegvisomant 15 mg [2-h oral glucose tolerance test: 10.3 +/- 0.7 (SMS), 8.9 +/- 0.7 (active), 7.2 +/- 0.7 (10 mg), 6.5 +/- 0.5 (15 mg), 8.0 +/- 0.8 (combined) (P = 0.02)].
    2 context sentences
    Summary · context
    Eleven patients with persistent disease despite previous therapy underwent the following fixed treatment algorithm: 1) on SMS therapy, 2) off therapy for 2 months, 3) 6-wk treatment with 10 mg/d pegvisomant, 4) 6-wk treatment with 15 mg/d pegvisomant, and 5) 3-month treatment with 15 mg pegvisomant plus SMS.
    Summary · context
    Blood was sampled in the fasting state and during an oral glucose tolerance test.
  12. 12HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, two-hour OGTT glucose was 6.5 +/- 0.5 during pegvisomant 15 mg/d versus 10.3 +/- 0.7 millimoles per liter during SMS.

    In plain wordsIn acromegaly patients, pegvisomant 15 mg/d produced lower glucose after a glucose test than the SMS phase.

    Peptide
    Pegvisomant
    Outcome
    DecreaseTwo-hour OGTT glucose at 15 mg/d versus SMS
    Study

    n = 11

    Comparator
    SMS therapy phase
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mg/d · 6 weeksAs given in this study (human).

    Measurements

    Two-hour OGTT glucose
    6.5 millimoles per liter
    15 mg
    Two-hour OGTT glucose
    10.3 millimoles per liter
    SMS

    Source sentences

    Summary
    Plasma glucose levels (millimoles per liter) were highest during SMS and lowest during pegvisomant 15 mg [2-h oral glucose tolerance test: 10.3 +/- 0.7 (SMS), 8.9 +/- 0.7 (active), 7.2 +/- 0.7 (10 mg), 6.5 +/- 0.5 (15 mg), 8.0 +/- 0.8 (combined) (P = 0.02)].
    2 context sentences
    Summary · context
    Eleven patients with persistent disease despite previous therapy underwent the following fixed treatment algorithm: 1) on SMS therapy, 2) off therapy for 2 months, 3) 6-wk treatment with 10 mg/d pegvisomant, 4) 6-wk treatment with 15 mg/d pegvisomant, and 5) 3-month treatment with 15 mg pegvisomant plus SMS.
    Summary · context
    Blood was sampled in the fasting state and during an oral glucose tolerance test.
  13. 13HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, total IGF-I was 376 during pegvisomant 10 mg/d versus 458 micrograms per liter during SMS therapy.

    In plain wordsIn acromegaly patients, total IGF-I was lower during pegvisomant 10 mg/d than during SMS therapy.

    Peptide
    Pegvisomant
    Outcome
    DecreaseTotal IGF-I at 10 mg/d versus SMS
    Study

    n = 11

    Comparator
    SMS therapy phase
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    10 mg/d · 6 weeksAs given in this study (human).

    Measurements

    Total IGF-I
    376 micrograms per liter
    pegvisomant
    Total IGF-I
    458 micrograms per liter
    SMS

    Source sentences

    Summary
    Total serum IGF-I levels (micrograms per liter) decreased after pegvisomant, but the lowest levels were obtained with cotreatment [458 +/- 67 (SMS), 562 +/- 78 (active), 376 +/- 51 (10 mg), 269 (15 mg), 195 +/- 24 (combined) (P < 0.0001)].
    1 context sentence
    Summary · context
    Eleven patients with persistent disease despite previous therapy underwent the following fixed treatment algorithm: 1) on SMS therapy, 2) off therapy for 2 months, 3) 6-wk treatment with 10 mg/d pegvisomant, 4) 6-wk treatment with 15 mg/d pegvisomant, and 5) 3-month treatment with 15 mg pegvisomant plus SMS.
  14. 14HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, endogenous GH was 14.6 during pegvisomant 10 mg/d versus 5.1 micrograms per liter during SMS therapy.

    In plain wordsIn acromegaly patients, natural GH was higher during pegvisomant 10 mg/d than during SMS therapy.

    Peptide
    Pegvisomant
    Outcome
    IncreaseEndogenous GH at 10 mg/d versus SMS
    Study

    n = 11

    Comparator
    SMS therapy phase
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    10 mg/d · 6 weeksAs given in this study (human).

    Measurements

    GH
    14.6 micrograms per liter
    pegvisomant
    GH
    5.1 micrograms per liter
    SMS

    Source sentences

    Summary
    Pegvisomant increased endogenous GH levels (micrograms per liter), which was countered by SMS cotreatment [5.1 +/- 1.3 (SMS), 8.9 +/- 2.9 (active), 14.6 +/- 4.9 (10 mg), 19.7 +/- 6.5 (15 mg), 11.8 +/- 2.8 (combined) (P < 0.01)].
    1 context sentence
    Summary · context
    Eleven patients with persistent disease despite previous therapy underwent the following fixed treatment algorithm: 1) on SMS therapy, 2) off therapy for 2 months, 3) 6-wk treatment with 10 mg/d pegvisomant, 4) 6-wk treatment with 15 mg/d pegvisomant, and 5) 3-month treatment with 15 mg pegvisomant plus SMS.
  15. 15HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, total IGF-I was 269 during pegvisomant 15 mg/d versus 458 micrograms per liter during SMS therapy.

    In plain wordsIn acromegaly patients, total IGF-I was lower during pegvisomant 15 mg/d than during SMS therapy.

    Peptide
    Pegvisomant
    Outcome
    DecreaseTotal IGF-I at 15 mg/d versus SMS
    Study

    n = 11

    Comparator
    SMS therapy phase
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    15 mg/d · 6 weeksAs given in this study (human).

    Measurements

    Total IGF-I
    269 micrograms per liter
    pegvisomant
    Total IGF-I
    458 micrograms per liter
    SMS

    Source sentences

    Summary
    Total serum IGF-I levels (micrograms per liter) decreased after pegvisomant, but the lowest levels were obtained with cotreatment [458 +/- 67 (SMS), 562 +/- 78 (active), 376 +/- 51 (10 mg), 269 (15 mg), 195 +/- 24 (combined) (P < 0.0001)].
    1 context sentence
    Summary · context
    Eleven patients with persistent disease despite previous therapy underwent the following fixed treatment algorithm: 1) on SMS therapy, 2) off therapy for 2 months, 3) 6-wk treatment with 10 mg/d pegvisomant, 4) 6-wk treatment with 15 mg/d pegvisomant, and 5) 3-month treatment with 15 mg pegvisomant plus SMS.
  16. 16HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, endogenous GH was 19.7 during pegvisomant 15 mg/d versus 5.1 micrograms per liter during SMS therapy.

    In plain wordsIn acromegaly patients, natural GH was higher during pegvisomant 15 mg/d than during SMS therapy.

    Peptide
    Pegvisomant
    Outcome
    IncreaseEndogenous GH at 15 mg/d versus SMS
    Study

    n = 11

    Comparator
    SMS therapy phase
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    15 mg/d · 6 weeksAs given in this study (human).

    Measurements

    GH
    19.7 micrograms per liter
    pegvisomant
    GH
    5.1 micrograms per liter
    SMS

    Source sentences

    Summary
    Pegvisomant increased endogenous GH levels (micrograms per liter), which was countered by SMS cotreatment [5.1 +/- 1.3 (SMS), 8.9 +/- 2.9 (active), 14.6 +/- 4.9 (10 mg), 19.7 +/- 6.5 (15 mg), 11.8 +/- 2.8 (combined) (P < 0.01)].
    1 context sentence
    Summary · context
    Eleven patients with persistent disease despite previous therapy underwent the following fixed treatment algorithm: 1) on SMS therapy, 2) off therapy for 2 months, 3) 6-wk treatment with 10 mg/d pegvisomant, 4) 6-wk treatment with 15 mg/d pegvisomant, and 5) 3-month treatment with 15 mg pegvisomant plus SMS.
  17. 17HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, total IGF-I was 195 with pegvisomant plus SMS versus 458 micrograms per liter during SMS alone.

    In plain wordsIn acromegaly patients, total IGF-I was lower with pegvisomant plus SMS than with SMS alone.

    Peptide
    Pegvisomant
    Outcome
    DecreaseTotal IGF-I with pegvisomant plus SMS versus SMS
    Study

    n = 11

    Comparator
    SMS therapy alone
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    15 mg · 3 monthsAs given in this study (human).

    Measurements

    Total IGF-I
    195 micrograms per liter
    combined
    Total IGF-I
    458 micrograms per liter
    SMS

    Source sentences

    Summary
    Total serum IGF-I levels (micrograms per liter) decreased after pegvisomant, but the lowest levels were obtained with cotreatment [458 +/- 67 (SMS), 562 +/- 78 (active), 376 +/- 51 (10 mg), 269 (15 mg), 195 +/- 24 (combined) (P < 0.0001)].
    1 context sentence
    Summary · context
    Eleven patients with persistent disease despite previous therapy underwent the following fixed treatment algorithm: 1) on SMS therapy, 2) off therapy for 2 months, 3) 6-wk treatment with 10 mg/d pegvisomant, 4) 6-wk treatment with 15 mg/d pegvisomant, and 5) 3-month treatment with 15 mg pegvisomant plus SMS.
  18. 18HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, endogenous GH was 11.8 with pegvisomant plus SMS versus 5.1 micrograms per liter during SMS alone.

    In plain wordsIn acromegaly patients, natural GH was higher with pegvisomant plus SMS than with SMS alone.

    Peptide
    Pegvisomant
    Outcome
    IncreaseEndogenous GH with pegvisomant plus SMS versus SMS
    Study

    n = 11

    Comparator
    SMS therapy alone
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    15 mg · 3 monthsAs given in this study (human).

    Measurements

    GH
    11.8 micrograms per liter
    combined
    GH
    5.1 micrograms per liter
    SMS

    Source sentences

    Summary
    Pegvisomant increased endogenous GH levels (micrograms per liter), which was countered by SMS cotreatment [5.1 +/- 1.3 (SMS), 8.9 +/- 2.9 (active), 14.6 +/- 4.9 (10 mg), 19.7 +/- 6.5 (15 mg), 11.8 +/- 2.8 (combined) (P < 0.01)].
    1 context sentence
    Summary · context
    Eleven patients with persistent disease despite previous therapy underwent the following fixed treatment algorithm: 1) on SMS therapy, 2) off therapy for 2 months, 3) 6-wk treatment with 10 mg/d pegvisomant, 4) 6-wk treatment with 15 mg/d pegvisomant, and 5) 3-month treatment with 15 mg pegvisomant plus SMS.
  19. 19HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, two-hour OGTT glucose was 8.0 with pegvisomant plus SMS versus 10.3 millimoles per liter during SMS alone.

    In plain wordsIn acromegaly patients, glucose after a glucose test was lower with pegvisomant plus SMS than with SMS alone.

    Peptide
    Pegvisomant
    Outcome
    DecreaseTwo-hour OGTT glucose with pegvisomant plus SMS versus SMS
    Study

    n = 11

    Comparator
    SMS therapy alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mg · 3 monthsAs given in this study (human).

    Measurements

    Two-hour OGTT glucose
    8 millimoles per liter
    combined
    Two-hour OGTT glucose
    10.3 millimoles per liter
    SMS

    Source sentences

    Summary
    Plasma glucose levels (millimoles per liter) were highest during SMS and lowest during pegvisomant 15 mg [2-h oral glucose tolerance test: 10.3 +/- 0.7 (SMS), 8.9 +/- 0.7 (active), 7.2 +/- 0.7 (10 mg), 6.5 +/- 0.5 (15 mg), 8.0 +/- 0.8 (combined) (P = 0.02)].
    1 context sentence
    Summary · context
    Eleven patients with persistent disease despite previous therapy underwent the following fixed treatment algorithm: 1) on SMS therapy, 2) off therapy for 2 months, 3) 6-wk treatment with 10 mg/d pegvisomant, 4) 6-wk treatment with 15 mg/d pegvisomant, and 5) 3-month treatment with 15 mg pegvisomant plus SMS.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.